Concord Biotech (BOM:543960) Long-Term Capital Lease Obligation : ₹6 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Long-Term Capital Lease Obligation?

Concord Biotech's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹6 Mil.

Concord Biotech's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 (₹16 Mil) to Dec. 2024 (₹0 Mil) but then increased from Dec. 2024 (₹0 Mil) to Mar. 2025 (₹6 Mil).

Concord Biotech's annual Long-Term Capital Lease Obligation increased from Mar. 2023 (₹2 Mil) to Mar. 2024 (₹19 Mil) but then declined from Mar. 2024 (₹19 Mil) to Mar. 2025 (₹6 Mil).

Concord Biotech Long-Term Capital Lease Obligation Historical Data

The historical data trend for Concord Biotech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Long-Term Capital Lease Obligation Chart

Concord Biotech Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

16.33

3.11

1.64

18.87

6.30

Concord Biotech Quarterly Data
	Mar20	Mar21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial									18.87	-	16.07	-	6.30

Concord Biotech (BOM:543960) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Concord Biotech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CONCORDBIO:India

Address

Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015

Website

https://www.concordbiotech.com

Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines